Codiak BioSciences
Edit

Codiak BioSciences

http://www.codiakbio.com/
Last activity: 13.09.2022
Tags:BioTechDesignDevelopmentMedTechPlatform
About Codiak BioSciences Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Mentions
28
Location: United States, Massachusetts, Cambridge
Employees: 51-200
Total raised: $300M
Founded date: 2015
Twitter
Facebook
LinkedIn
Email

Investors 2

Funding Rounds 4

DateSeriesAmountInvestorsDeal News
14.10.2020IPO$82M--
29.11.2017Series C$77M-finsmes.co...
26.01.2016Series B$61M-finsmes.co...
18.11.2015Series A$80M-vcnewsdail...

Mentions in press and media 28

DateTitleDescriptionSource
13.09.2022Two biotechs go for pub­lic of­fer­ings; Pfiz­er part­ner ex...Af­ter the FDA ap­proved Re­vance’s Daxxi­fy as a longer-last­ing al­ter­na­tive to Ab­b­Vie’s cash ...endpts.com...
13.09.2022Codiak Announces Pricing of $20 Million Public Offering of C...CAMBRIDGE, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. CDAK ("Codiak&quo...einpresswi...
04.11.2021Al­pha­bet kick­starts new AI drug dis­cov­ery out­fit with ...Last sum­mer marked a ma­jor break­through in drug dis­cov­ery when Deep­Mind, a pre­dic­tive mod­el...endpts.com...
04.11.2021More than a year af­ter trim­ming R&D unit, Iron­wood ad...Iron­wood Phar­ma­ceu­ti­cals has walked a less-than-easy path the past few years with a proxy-dri­v...endpts.com...
04.11.2021Lon­za en­ters the ex­o­some ther­a­py space with ac­qui­si­...In an­tic­i­pa­tion of tack­ling the man­u­fac­tur­ing prob­lems that come with ex­o­some ther­a­peu...endpts.com...
04.11.2021Al­pha­bet kick­starts new AI drug dis­cov­ery out­fit with ...Moderna has drawn plaudits from around the industry and the globe for its Covid-19 vaccine, and it r...endpts.com...
04.11.2021Al­pha­bet kick­starts new AI drug dis­cov­ery out­fit with ...Moderna’s stock $MRNA plunged more than 14% in premarket trading on Thursday after the biotech cut i...endpts.com...
04.11.2021Gen­Script drops a mod­est in­vest­ment in­to its sup­ply ca...Ray Miller New Jer­sey’s Gen­Script an­nounced the open­ing of a 50,000-square-foot fa­cil­i­ty for...endpts.com...
04.11.2021Blue­bird bio com­pletes split in­to two com­pa­nies; BeiGen...Blue­bird bio has been of­fi­cial­ly split in half. Both sides of the once-sin­gu­lar cell and gene...endpts.com...
04.11.2021Tout­ing close ties to biotech in­cu­ba­tors, Mis­sion Bio­C...Be­fore mov­ing to shiny new of­fices on their ven­ture dimes, many biotech star­tups trace their be...endpts.com...
Show more